Navegando por Palavras-chave "SYSTEMIC LUPUS ERYTHEMATOSUS"

Agora exibindo 1 - 3 de 3
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Mortality Profile Related to Systemic Lupus Erythematosus: A Multiple Cause-of-death Analysis
    (J Rheumatol Publ Co, 2012-03-01) Souza, Deborah C. C. [UNIFESP]; Santo, Augusto H. [UNIFESP]; Sato, Emilia I. [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    Objective. To analyze the mortality profile related to systemic lupus erythematosus (SLE) in the state of São Paulo, Brazil.Methods. for the 1985-2007 period, we analyzed all death certificates (n = 4815) on which SLE was listed as an underlying (n = 3133) or non-underlying (n = 1682) cause of death. We evaluated sex, age, and the causes of death, comparing the first and last 5 years of the period, as well as determining the observed/expected death ratio (O/E ratio).Results. for SLE as an underlying cause, the mean age at death was 35.77 years (SD 15.12) and the main non-underlying causes of death were renal failure, circulatory system diseases, pneumonia, and septicemia. Over the period, the proportional mention of infectious causes and circulatory system diseases increased, whereas renal diseases decreased. for SLE as a non-underlying cause of death, the most common underlying causes of death were circulatory, respiratory, genitourinary, and digestive system diseases, and certain infections. the overall death O/E ratio was > 1 for renal failure, tuberculosis, septicemia, pneumonia, and digestive system diseases, as well as for circulatory system diseases at < 50 years of age, particularly acute myocardial infarct.Conclusion. Unlike in developed countries, renal failure and infectious diseases are still the most frequent causes of death. the increase in SLE deaths associated with infection, especially pneumonia and septicemia, is worrisome. the judicious use of immunosuppressive therapy together with vigorous treatment of cardiovascular comorbidities is crucial to the successful management of SLE and to improving survival of patients with SLE. (First Release Jan 15 2012; J Rheumatol 2012;39:496-503; doi:10.3899/jrheum.110241)
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    SYSTEMIC LUPUS-ERYTHEMATOSUS - A FAMILY STUDY OF 25-PROBANDS
    (Clinical & Exper Rheumatology, 1991-09-01) Sato, Emilia Inoue [UNIFESP]; Atra, Edgard [UNIFESP]; Gabriel, A.; Masi, A. T.; UNIV ILLINOIS; Universidade Federal de São Paulo (UNIFESP)
    We studied 120 first-degree relatives (FDRs) of 25 systemic lupus erythematosus (SLE) probands and 59 non-genetically associated individuals who were in close contact with the SLE patients. A significantly greater frequency of antinuclear antibody (ANA) positivity was found among the FDRs than in the control group (p < 0.01). No significant difference was found in ANA positivity between the female and male FDRs. Articular complaints or Raynaud's phenomenon were observed in 15% of the FDRs and in only 2% of the controls (p < 0.05). Female FDRs had a greater number of rheumatic complaints than male FDRs (p < 0.05) and a significant association was found between rheumatic complaints and ANA positivity (p < 0.001) among the total FDRs.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    TREATMENT OF THE CUTANEOUS LESIONS OF SYSTEMIC LUPUS-ERYTHEMATOSUS WITH THALIDOMIDE
    (Clinical & Exper Rheumatology, 1993-09-01) Atra, Edgard [UNIFESP]; Sato, Emilia Inoue [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    Twenty three patients with SLE and cutaneous lesions not responsive to chloroquine, photoprotectors and corticosteroid in doses < 0.5 mg/kg/day were treated with thalidomide 300 mg/day. Three patients presented side effects and had to discontinue treatment. Eighteen of the remaining 20 patients (90%) had complete remission of the cutaneous lesions and 2 had partial improvement. Another important parameter of improvement was a reduction in the average prednisone dose required from 40.5 mg/day to 17.4 mg/day. The most frequent side effects were drowsiness in 52% of cases and abdominal distention in 22%. These symptoms were reversed by dose reductions in all but one patient. Thalidomide was shown to be efficient in the treatment of cutaneous lesions unresponsive to more usual treatments.